Sankyo Company, Limited

Ube Industries, Inc.

Nobuyoshi Iwata

Mitsuo Nagano

Kenji Yoshimi

Koichi Kojima

Kazuo Koyama

Yoshiko Kubo

Shigeo Amemiya

Junichi Sakai

Masao Kozuka

Kazuo Kobayashi

Takeo Kobayashi

Tomio Kimura

Hiroyuki Koike

Takeshi Oshima

Masakatsu Kaneko

Mitsuo Yamazaki

Yasuhiro Morisawa

Katsunori Kato

Yasuo Shimoji

Keiichi Tabata

Takashi Kobayashi

Misako Kimura

Yoshinobu Murofushi

Fumio Nakagawa

Seiji Kumakura

Kuniyuki Tomita

Isao Nakayama

Kanichi Nakamura

Toshiyuki Tonohiro

Takao Hara

Compounds of formula (I): ##STR1## wherein R.sup.1 is hydrogen, halogen or alkyl; R.sup.2 is hydrogen, alkyl, optionally substituted phenyl or a heterocycle; or R.sup.1 and R.sup.2 together form a group of formula --CR.sup.4 .dbd.CR.sup.5 --CR.sup.6 .dbd.CR.sup.7 --, where R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are hydrogen, halogen, alkyl group, alkoxy, halomethyl, alkylamino, dialkylamino, hydroxy, nitro, aliphatic carboxylic acylamino or amino; and R.sup.3 is piperidyl, substituted piperidyl or quinuclidinyl. The compounds are useful in the treatment and prophylaxis of cognitive disorders, notably senile dementia, including Alzheimer's disease. Processes for preparing the compounds are also provided.

Quinuclidinyloxy-isoxazole compounds and their therapeutic uses

Compounds of formula (I): ##STR1## [in which: either (a) the dotted line ( ) is a single bond; A=is oxygen; and B is a group of formula (II): ##STR2## (in which m is 0 and n is 0 or 1) or (b) the dotted line ( ) is a double bond; A=is said group of formula (II) in which m is 1 and n is 0 or 1; and B is absent; and R.sup.1 is hydrogen, halogen, alkyl, alkenyl, alkynyl, optionally substituted benzyl or optionally substituted phenyl; R.sup.2 is hydrogen, halogen, alkyl, optionally substituted phenyl or heterocyclic; or R.sup.1 and R.sup.2, together with the carbon atoms to which they are attached, are a hydrocarbon ring fused to the isoxazole ring; R.sup.3 and R.sup.4 are each hydrogen, alkyl, optionally substituted benzyl or optionally substituted phenyl; or R.sup.3, R.sup.4 and the nitrogen atom to which they are attached together represent an alicyclic amino group]; and salts thereof may be used for the treatment of cerebral circulatory problems and for use as centrally acting muscle relaxants.

Isoxazole derivatives for use as cerebro-active drugs and central muscle

A method of treating depression comprising administering to a patient an effective amount of a compound of the formula (Ib): ##STR1## wherein R.sup.1b is hydrogen, halogen, C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkynyl, an unsubstituted benzyl group, a substituted benzyl having at least one substitutent (b) selected from the group consisting of C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy, hydroxy, halogen, nitro, amino and C.sub.2 -C.sub.4 aliphatic carboxylic acylamino; unsubstituted phenyl or a substituted phenyl having at least one substitutent (b); R.sup.2b is hydrogen, C.sub.1 -C.sub.4 alkyl, unsubstituted phenyl, substituted phenyl having at least one substitutent (b), unsubstituted 5- or 6- membered heterocyclic having an oxygen, sulfur or nitrogen as a heteroatom, or substituted 5- or 6- membered heterocyclic having an oxygen, sulfur or nitrogen as a heteroatom and having at least one substitutent (b); and R.sup.3b and R.sup.4b are the same or different and each is hydrogen, C.sub.1 -C.sub.4 alkyl, unsubstituted benzyl, substituted benzyl having at least one substituent (b), unsubstituted phenyl, or substituted phenyl having at least one substitutent (b); or R.sup.3b, R.sup.4b and the nitrogen atom to which they are attached together represent an alicyclic amino group having a total of 5 or 6 ring atoms, or which one ring atom is the nitrogen atom and one ring atom is optionally an additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, the alicyclic amino group being unsubstituted or, where there is an additional nitrogen heteroatom, the alicyclic amino group having a C.sub.1 -C.sub.3 alkyl substitutent on the additional nitrogen heteroatom; or a pharmacologically acceptable acid addition salt thereof.

Use of isoxazolin-3-one derivatives as antidepressants

A method of treating depression comprising administering to a patient an effective antidepressive amount of a compound of the formula ##STR1## wherein either (i) the endocyclic dotted line (  ) is a double bond; the exoxyclic dotted line (  ) is a single bond;

A method of treating depression comprising administering to a patient an effective antidepressive amount of a compound of the formula (I) ##STR1## wherein the endocyclic dotted line ##STR2## is a single bond; the exocyclic dotted line ##STR3## is a double bond; A is oxygen; B is a group of the formula (II) ##STR4## wherein m is 0 and n is 0 or 1; R.sup.3, R.sup.4 and the nitrogen to which they are attached together represent an alicyclic amino having a total of 5 or 6 ring atoms, of which one ring atom is the nitrogen and one ring atom is optionally an additional heteroatom selected from the group consisting of nitrogen, oxygen and sulfur, the alicyclic amino being unsubstituted or, where there is an additional nitrogen heteroatom, the alicyclic amino having as a substituent a C.sub.1 -C.sub.3 alkyl on the additional nitrogen heteroatom; R.sup.1 is hydrogen or halogen; and R.sup.2 is an unsubstituted phenyl, a substituted phenyl having a substituent selected from the group consisting of C.sub.1-3 alkyl, C.sub.1-3 alkoxy, halogen and nitro, an unsubstituted 5- or 6-membered heterocyclic group having one or more of oxygen, sulfur or a nitrogen as heteroatoms, or a substituted 5- or 6-membered heterocyclic group having one or more of oxygen, sulfur or a nitrogen as heteroatoms and having at least one substituent selected from the group consisting of C.sub.1 -C.sub.3 alkyl, C.sub.1-3 alkoxy, halogen and nitro; or a pharmaceutically acceptable acid addition salt thereof.

Prostaglandin derivatives having an oxo group at specified positions in the .alpha. side chain have a variety of physiological effects, notably a strong anti-ulcer activity accompanied by a limited ability to inhibit blood platelet aggregation.

Prostaglandin derivatives, their preparation and their therapeutic use

Prostaglandin derivatives, and specifically derivatives of isocarbacyclin, have an optionally substituted methylene group as a substituent on the .alpha.-carbon atom of the .alpha.-side chain. They have a variety of physiological effects, notably a strong ability to inhibit blood platelet aggregation and a strong anti-ulcer activity.

Prostaglandin derivatives, their preparation and use

Compounds of formula (I): ##STR1## (wherein R.sup.1 and R.sup.2 are hydroxy, alkoxy, aryloxy or acyloxy or R.sup.2 is hydrogen, R.sup.3 is hydrogen or alkyl and R.sup.4 and R.sup.5 are hydrogen or various organic substituents) have valuable antidepressant activity and may be used in the treatment of mental depression.

Cyclopenta[d]pyrimidine derivatives and use as antidepressants

Fused ring compounds of formula (I): ##STR1## (where R.sup.1 -R.sup.4, X.sup.1 and X.sup.2 represent hydrogen or various substituents, n and m are 1-3 and 2-7 respectively, the dotted lines are double or single bonds and Y is one oxygen or two hydrogens) have magnificent anti-arrhythmic activity, diuretic activity and the ability to improve brain function.

Fused 5 ring heterocyclic compounds, their preparation, and their

Griseolic acid derivatives of formula (I): ##STR1## wherein A represents: ##STR2## have enzyme-inhibitory activity, especially against cAMP PDE and cGMP PDE. When formulated as compositions with appropriate carriers or diluents, they may be used for the treatment of a variety of organic disorders and show toxicities less than griseolic acid itself.

Griseolic acid derivatives, and their use as enzyme inhibitors

Growing community of inventors

Tokyo, Japan

Nobuyoshi Iwata